Things that impact racial, ethnic disparities in cancer survivalOne study seeks to understand the underlying causes of racial and ethnic disparities in cancer survival. The results may be surprising.
The price of surviving childhood cancerSurviving cancer is challenging enough, but now a recent report highlights the fact that survivors face double the chronic health challenges of the general population as a result of curative cancer therapies.
Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Five rules for payer success in oncologyPayers must reinvent efforts to reduce cancer cost and increase quality for a value-based care world. Here’s five rules to follow.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.